Log in
(Ad)
I call it my "Dividend Map", and I'll show you exactly where to find the safest companies that pay the highest yields. (HINT: Texas has 6 of these companies sending huge payouts that average 77%!). I'm willing to send you my Map... but only if you

NASDAQ:ANDS - Anadys Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ANDS
CUSIPN/A
Phone+1-858-5303600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ANDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANDS and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Anadys Pharmaceuticals (NASDAQ:ANDS) Frequently Asked Questions

What is Anadys Pharmaceuticals' stock symbol?

Anadys Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANDS."

Has Anadys Pharmaceuticals been receiving favorable news coverage?

Press coverage about ANDS stock has trended negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Anadys Pharmaceuticals earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Anadys Pharmaceuticals.

What is Anadys Pharmaceuticals' official website?

The official website for Anadys Pharmaceuticals is http://www.anadyspharma.com/.

How can I contact Anadys Pharmaceuticals?

Anadys Pharmaceuticals' mailing address is Suite 200, 5871 Oberlin Drive, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-5303600.


MarketBeat Community Rating for Anadys Pharmaceuticals (NASDAQ ANDS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Anadys Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel